Aurinia Pharmaceuticals INC DEF 14A proxy statements

Aurinia Pharmaceuticals announces its 2026 Annual General Meeting to be held virtually on June 3, 2026, featuring director elections and executive compensation votes.

Leading independent proxy advisor Glass Lewis recommends Aurinia Pharmaceuticals shareholders vote in favor of all board proposals at the upcoming 2025 Annual General Meeting.

Aurinia Pharmaceuticals Inc. has filed a definitive proxy statement with the SEC related to its upcoming annual meeting.

Aurinia Pharmaceuticals seeks shareholder approval for an amendment to its Equity Incentive Plan and reports significant corporate governance changes, including a reduced board size and new director nominees.

Aurinia Pharmaceuticals addresses concerns regarding Lucien Selce's proposals, highlighting his background and lack of transparency, while reaffirming the company's strategic direction and recommending shareholders vote for the current board.

Aurinia Pharmaceuticals is reducing the proposed increase in shares reserved for issuance under its Equity Incentive Plan from 11,375,000 to 8,500,000 shares.

Aurinia Pharmaceuticals Inc. will hold its Annual General Meeting on June 14, 2024, with shareholders voting on director elections, auditor appointment, executive compensation, and an equity incentive plan amendment.

Aurinia Pharmaceuticals is asking shareholders to approve an amendment to its Equity Incentive Plan to increase the maximum number of common shares reserved for issuance.